1910

1910's PEGASUS™ and CANDID-CNS™ AI models achieve significant breakthroughs, leading to successful preclinical and early clinical validation of multiple drug candidates. This attracts a major pharmaceutical partnership with substantial upfront payments and milestones, pushing revenue to over $100M and justifying a $1B+ valuation at 10x revenue multiple, well above the current $250M.

The company continues to grow its platform-as-a-service and co-discovery models, securing additional partnerships with mid-sized biopharma companies. Revenue grows steadily to ~$25M-$30M within two years, and the company raises a Series B round at a $375M valuation, reflecting solid execution but still early-stage drug pipeline progress.

Despite promising AI models, the long and costly drug development cycle proves challenging. Competitors like Recursion Pharmaceuticals or Insilico Medicine gain significant market share, or a major incumbent like Microsoft (despite being a partner) expands its own AI drug discovery offerings. This leads to slower-than-expected revenue growth, a challenging Series B fundraise, and a down round to a $62.5M valuation, significantly eroding common stock value given the preference stack.